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By combining the sciences of nutrition, bioinformatics, genomics, population genetics,
and epidemiology, nutrigenomics is improving our understanding of how diet and nutrient
intake can interact with or modify gene expression and disease risk. In this review, we
explore various approaches to examine gene–nutrient interactions and the modifying role
of nutrient consumption, as they relate to nutrient status and disease risk in human pop-
ulations. Two common approaches include the use of SNPs in candidate genes to identify
their association with nutritional status or disease outcomes, or genome-wide association
studies to identify genetic polymorphisms associated with a given phenotype. Here, we
examine the results of various gene–nutrient interaction studies, the association of genetic
polymorphisms with disease expression, and the identification of nutritional factors that
modify gene-dependent disease phenotypes. We have focused on specific examples from
investigations of the interactions of folate, B-vitamin consumption, and polymorphisms in
the genes of B-vitamin dependent enzymes and their association with disease risk, fol-
lowed by an examination of the strengths and limitations of the methods employed. We
also present suggestions for future studies, including an approach from an on-going large
scale study, to examine the interaction of nutrient intake and genotypic variation and their
impact on nutritional status.
Keywords: folate metabolism, folate, folic acid, functional genomics, candidate gene, genome-wide association
studies
APPLICATION OF GENOMICS TO ADDRESS PUBLIC HEALTH
Specific sub-populations may be genetically pre-disposed to high
or low status for specific nutrients. New high-throughput sequenc-
ing and bioinformatics tools for genetic analysis have opened the
door to performing detailed analyses of the interrelationships
among dietary intake, nutritional status, and genetic polymor-
phisms. Data from these studies may in turn be used to inform
nutrition policies to maximize public health benefits. For exam-
ple, we are currently identifying single nucleotide polymorphisms
(SNPs) that predict an individual’s response to folic acid intake
in the Canadian population using samples from the Canadian
Health Measures Survey cycle 1 (1). In this review, we explore
various approaches to examine gene–nutrient interactions and
the effect of nutrient consumption on gene expression and func-
tion as they relate to disease risk in human populations. We
present specific examples from investigations of the interactions
of folate and B-vitamin consumption and polymorphisms in the
genes of B-vitamin dependent enzymes and their association with
disease risk.
GENE–ENVIRONMENT INTERACTION
Since the advent of DNA sequencing, numerous genetic polymor-
phisms have been identified that are associated with human dis-
eases including developmental anomalies, diabetes, cardiovascular
disease, and cancer (2, 3). SNPs can play an integral role in pheno-
typic plasticity and contribute to much of the genetic variability
observed in phenotypes dependent on gene–environment inter-
actions (4). Although SNPs have been associated with chronic
diseases or disorders, in general, a single SNP or group of SNPs
(haplotype) is rarely by itself causal (5). Put simply, SNPs are often
necessary,but not sufficient, for the development of a given disease.
The majority of chronic diseases are multifactorial and depend
on gene–environment interactions [(5, 6); Figure 1]. The influ-
ence of environmental factors alters the phenotypic expression
of a genotype. In the context of disease, these interactions may
result in increased susceptibility or resistance depending on both
the genotype and environmental exposure. Environmental factors
include any non-genetic contribution to a phenotype, which could
directly influence the output of a genetic pathway to prevent, ini-
tiate, aggravate, or mitigate a pathological response. These can be
under an individual’s control, such as behavioral or nutritional
factors, or they may be beyond an individual’s control, such as
climate change or unintended exposure to toxins (7).
The outcome of gene–environment interactions can cause a
change in genotype ranking (genotypic advantage changes in dif-
ferent environments), a change in scale of phenotypic expression,
or a combination of both. Various experimental models of gene–
environmental interaction have been developed to account for
ways in which genetic effects can be modified by environmen-
tal exposures, taking into account the number of exposures, the
level of exposure, the timing of exposure, and the model on which
the genetic effects are based (8, 9). For example, the most basic
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FIGURE 1 |Three scenarios that influence phenotypic expression, such
as environment only influence, genotype only influence, and the
influence of gene×environment interaction.
gene–environment interactions include a single environmental
factor that alters the expression of a single gene to influence pheno-
type. In the absence of one or the other, the disease will not occur.
More commonly, the expression of a disease phenotype, such as
diabetes or cardiovascular disease, is dependent on multiple genes
(gene–gene interactions), and single or multiple environmental
exposures. In these more complex conditions, any given individ-
ual gene or environmental factor is a minor contributor to disease
expression; rather, it is the combined effect of multiple genes modi-
fied by specific environmental triggers that, when combined, result
in disease.
It must be mentioned that one mechanism by which envi-
ronmental factors can influence gene expression is through epi-
genetics. Epigenetics is defined as a change in gene expression
in the absence of a change to the DNA sequence (10). Epige-
netic regulation of gene expression can occur by DNA methy-
lation, methylation or other post-translational modifications of
histones, or the activation of microRNAs. In addition, recent
studies have revealed that epigenetic variation can interact with
genetic variation in the expression of a disease phenotype (11).
The concept of epigenetic gene regulation is pertinent in the con-
text of folate metabolism since folate status influences cellular
methylation capacity (Figure 2; see also section: Case in point:
Nutrigenomic approaches in the study of folate-related pathologies).
However, for succinctness, we will limit the scope of our discus-
sion to the interaction between environmental factors and genetic
variants.
NUTRIENT DEPENDANT GENETIC ASSOCIATIONS
Nutrients represent a large, varied, and ubiquitous group of envi-
ronmental factors involved in gene–environment interactions. The
study of gene–nutrient interactions has begun to identify the
underlying roles of specific nutrients in disease and developmental
disorders. By understanding the mechanisms underlying gene–
nutrient interactions, the nutrition of both individuals and pop-
ulations may be tailored to reduce the burden of chronic disease.
These studies are often based on observed associations between
the intake and status of a nutrient with risk for a disease. These
associations are often initially observed in case–control, cohort, or
longitudinal studies, as well as in animal models. Though, these
studies are unable to pinpoint the underlying genetic factors con-
tributing to phenotype expression, they link specific nutrients to a
particular disease and provide the foundation on which hypothesis
driven experiments can be developed. For example, these types of
studies have demonstrated an association between higher serum
levels of Vitamin A and reduced risk of lung cancer (12), nutrition
in early development and later cognitive development (13), and
low maternal folate status and increased neural tube defect (NTD)
risk (14).
Two approaches to study how nutrients interact with genes to
influence phenotype have been widely applied. The first is the can-
didate gene approach, which examines the relationship between
SNPs in candidate genes (usually nutrient-related genes) and dis-
ease risk. The second, GWAS, surveys genetic polymorphisms in a
genome-wide fashion to assess their association with disease risk
(15,16). Finally, the modifying effect of nutrient intake on the asso-
ciations between genetic polymorphisms and disease phenotype,
or its effect on gene expression in disease can also be examined.
With the increasing speed and accuracy of whole genome sequenc-
ing, the ability to identify, and characterize these interactions has
increased dramatically.
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FIGURE 2 | Cytoplasmic folate-mediated one-carbon metabolism is
required for de novo purine, thymidylate, and methionine synthesis.
Cellular methylation potential is dependent on the production of
S-adenoyslmethionine (AdoMet), the major methyl donor in the cell.
Methionine is generated when homocysteine is remethylated. A methyl
group can be transferred from 5-methyltetrahydrofolate (THF) by methionine
synthase (MS). 5-methylTHF is produced by methylene THF reductase
(MTHFR) from the folate metabolic pathway. In the liver and kidney,
homocysteine can also be remethylated by betaine:homocysteine
methyltransferase (BHMT), a reaction that depends on choline-derived
betaine as the methyl donor (not shown). Methionine is converted to AdoMet,
from which methyltransferases (MT) transfer methyl groups to acceptor
molecules. Acceptor molecules include DNA, RNA, histones and other
proteins, and other small molecules. The reaction produces
S-adenosylhomocysteine (AdoHcy) that can be converted to homocysteine.
TS, thymidylate synthase; MTHFD1, methylene THF dehydrogenase 1.
FUNCTIONAL GENOMICS FOR NUTRIGENOMICS
With the development of high-throughput, genomic sequencing
technologies, it is feasible to examine links among nutrition, genet-
ics, and phenotype. The majority of nutrigenomic studies have
used either a candidate gene or genome-wide association study
(GWAS) approach to examine the interrelationship among SNPs
or other genetic polymorphisms, nutrient intake, nutrient status,
and disease (Table 1).
Candidate gene association studies are preferred when the
functional relationship of the target genes with an outcome is
known (17, 18). The reliance on sometimes limited a priori infor-
mation and the inability to consider all causative genes for a
given trait may hinder the scope of candidate gene studies (18–
20). New sequencing techniques with faster analysis times are
addressing this criticism, in part, by providing a means to eco-
nomically examine many genetic variants within a candidate gene
and expanded sets of candidate genes quickly. Unlike candidate
gene studies, GWAS require no prior knowledge of a gene’s func-
tional relationship to a given nutrient. In a GWAS, a suite of
genetic markers, commonly SNPs, is screened to determine if
the frequency of allele variants is significantly different between
the case and control groups (21). Of the many advantages of
GWAS, the ability to compare SNP allele frequency with quan-
titative environmental and phenotypic data may be the most
important.
Finding which loci in a suite of 100,000 (or more) markers
have a significant association with a phenotype presents a difficult
statistical problem, similar to finding a needle in a haystack. The
statistical power of a GWAS is a function of sample size, effect
size, causal allele frequency, and marker allele frequency and its
correlation with causal variants. When examining multiple asso-
ciations, GWASs can be fundamentally underpowered when the
association is of modest effect (22). Although the action of mul-
tiple factors (genetic or non-genetic), incomplete penetrance, and
modest effects reduce analytical power, proper study design, with
subjectively selected (large) population sizes, can overcome these
limitations (23). However, even in cases with adequate sample
size, GWAS have a high potential for false-positive results because
of the massive number of markers and statistical tests applied
(24). The risk of false positives can be avoided through proper
quality control and study design, including using appropriate ana-
lytical methods to correct for multiple testing [e.g., Bonferroni
corrected p-value, false discovery rate, permutation testing, Bit-
Force (25); network-assisted investigation (26); high-dimensional
vectors (27)].
The GWAS approach has evolved with new sequencing and
computational technology, and now includes random SNP array
selections, SNP functional predictions, and exomic SNP analyses
that theoretically cover only coding regions of the genome. In these
approaches, tag SNPs, a single-marker in a region of high linkage-
disequilibrium that can be used to represent the allele frequencies
of a group of SNPs, are popular as they dramatically reduce the
time and costs associated with examining suites of genetic markers
without losing resolution (28).
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Table 1 | A comparison of two major methods used to conduct gene association studies, candidate gene studies, and genome-wide association
studies.
GENIC ASSOCIATION APPROACH
Candidate gene studies
Methodology Examine associations between genetic polymorphisms and environmental interactions within pre-specified genes of interest
Hypothesis driven, case–control for binary outcomes or single cohort for continuous associations
Requires a priori knowledge of functional relationship between genes and target traits
Increasingly, relationship information is available in online databases
Limitations Reliance on existing information may limit scope of examined causative genes
Initial costs associated with identifying target genes and their function can be high if not previously published
Genome-wide association studies (GWAS)
Methodology Examines many (tens or hundreds of thousands) of genetic variants
Contrast two large groups of individuals using case vs. control or a continuous outcome to determine if allelic patterns are significantly
associated with a trait of interest
Requires no prior knowledge of relationship between gene function and phenotypic traits
Limitations Requires rigorous quality control to limit false-positive results caused by multiple pairwise comparisons
Large dataset size, lack of functional model testing and confounding biological and environmental factors that are not, or cannot be
considered can lead to erroneous associations
Common genetic variants used for some GWAS may not play a role in explaining the heritable variation of common disease
CASE IN POINT: NUTRIGENOMIC APPROACHES IN THE
STUDY OF FOLATE-RELATED PATHOLOGIES
Folate is an essential water-soluble B-vitamin that is required
for metabolic one-carbon transfers in the de novo synthesis of
purines, thymidylate, and methionine [Figure 2; (29)]. As such,
adequate folate consumption is essential for the synthesis, stabil-
ity, and repair of DNA (29). In conditions of folate deficiency,
uracil can be incorporated into DNA in the absence of thymidy-
late, which can lead to DNA strand breakage and reduced DNA
repair. Reduced purine synthesis results in reduced cell prolifera-
tion, cell stasis, and death. Folate deficiency also results in increased
homocysteine production, a one-carbon metabolism by-product
related to cardiovascular disease and other pathologies, due to
reduced methionine synthesis (30–32). Reduced methionine syn-
thesis limits the availability of S-adenosylmethionine for cellular
methylation reactions. Folate deficiency, resulting from inadequate
intake or genetic polymorphisms in folate-dependent genes, is
associated with increased risk for NTDs, cancer, cardiovascular
diseases, and other chronic diseases.
Folate-dependent one-carbon metabolism and homeostasis
requires a number of transporters, enzymes, and other nutri-
ent co-factors. Nearly all folate-related genetic studies have used
candidate gene or GWAS approaches to identify genetic markers
associated with a folate-dependent disease or for the identifica-
tion of associations among nutrient intake, folate-related genes,
and functional outcomes. Screening of more than 1500 SNPs
identified in folate and other B-vitamin metabolic pathways has
revealed ~150 SNPs with significant associations with pathological
endpoints (33, 34). Commonly, studies have either examined the
relationship between one or a few genes and nutrient status and/or
disease. Others have performed large GWAS analyses to identify
the association of genetic polymorphisms with a single phenotype
(e.g., disease or nutritional status), but they do not consider con-
founding variants. The limitations of these studies include limited
population size, limited number of candidate genes (1–10, e.g.,
MTHFR, Methylenetetrahydrofolate reductase, studies; Table 2)
and/or lack of dietary/supplement intake data or status data. Here,
we will discuss three diseases for which relationships with folate
and folate-dependent genes have been studied: NTDs; intestinal
cancers; and, cardiovascular disease.
NEURAL TUBE DEFECTS
Folate consumption and status during the peri-conceptional
period has long been associated with a reduction in developmen-
tal anomalies, including NTDs (14, 40–42). During pregnancy,
NTDs occur between 21 and 28 days after conception if the neural
plate fails to fold properly to form the neural tube, the precur-
sor of the spinal cord and brain. When the neural tube fails to
close, numerous NTD defects can arise including spina bifida
and anencephaly (43). Adequate maternal peri-conceptional folic
acid supplementation significantly reduces the risk of primary or
recurrent NTDs (14, 40). In an effort to reduce the number of
NTD-affected pregnancies, many countries, including Canada and
the United States, have mandated folic acid fortification of white
flour and other cereal products (44–46). In Canada, NTD inci-
dence has decreased by ~45% since the start of fortification (47).
The specific mechanism(s) by which folate prevents NTDs remains
poorly understood, but its role in nucleotide synthesis, DNA repair
and cellular methylation reactions are likely important.
The early observation of a high recurrence rate of NTDs
pointed to possible genetic contributors to pathogenesis. Numer-
ous studies have sought to identify the underlying genetic factors
influencing NTD prevalence (48–52). The genetic link combined
with the evident association between maternal folate status and
NTDs led to the evaluation of candidate genes directly or indi-
rectly involved in the folate metabolic pathway, including MTHFR,
methionine synthase (MTR), betaine–homocysteine methyltrans-
ferase (BHMT ), and serine hydroxymethyltransferase (SHMT ) to
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Table 2 | Major findings from association studies between MTHFR gene variants and two proof of principle diseases, neural tube defects, and
cancer risk, including sample size, significance (as p or 95% confidence interval), and odds ratio (OR).
Research Study Approach Findings Sample Size Significance OR
MTHFR AND NTDs
Boyles et al. (35) GWAS, clinical
sample population
No significant MTHFR SNP (rs1801133)/NTD risk associations
in individuals not taking maternal folate supplements
Total: 304 p: 0.203
Shaw et al. (33) Candidate gene,
large sample
population
Significant association between MTHFR SNP (rs1801133) and
NTD risk. No link between intake and allele frequency
Cases: 259,
controls: 359
95% CI:
1.2–3.1
2.0
Pangilinan et al. (34) tagSNP Significant association between MTHFR SNPs (rs17037425,
rs17367504) and NTD risk
Cases: 301,
controls: 341
p: 0.0068,
p: 0.0081
MTHFR AND CANCER RISK
Vollset et al. (36) GWAS No correlations between gastric cancer and plasma folate, total
homocysteine and serum B12. Slight increase in gastric cancer
risk with MTHFR (rs1801133).
Cases: 245,
controls: 631
p: 0.04 1.47
Ibiebele et al. (37) Candidate gene No link between MTHFR (rs1801131, rs1801133) and
esophageal adenocarcinomas.
Cases: 881,
controls: 1507
p: 0.22, p: 0.72
Terry et al. (38) Candidate gene MTHFR SNPs (rs1801131, rs1801133) showed no significant
association with increased ovarian cancer risk.
Cases: 1642,
controls: 2068
p: 0.59, p: 0.58
Han et al. (39) GWAS Link between MTHFR (rs1801131) and colorectal adenoma in
individuals with extremely low folate intake.
Case: 1331,
controls: 1501
p: 0.02
name a few (33, 35, 53). The most compelling observations have
been made for the MTHFR C677T variant, for which TT homozy-
gosity has been significantly associated with NTDs (54). While the
cause of folate-dependent NTDs remains unknown, the TT geno-
type results in a thermolabile enzyme and reduced folate metab-
olism, which may reduce cell proliferation or cellular methylation
reactions during embryonic development. Other folate metabolic
gene variants including methylenetetrahydrofolate dehydroge-
nase 1 (MTHFD1), dihydrofolate reductase (DHFR), methionine
synthase reductase (MTRR), and the transcobalamin II recep-
tor (TCblR) have been associated with NTDs using candidate
gene/SNP analysis (55–57).
Candidate gene studies and GWAS to identify SNPs associ-
ated with NTD risk have yielded variable results. Three promi-
nent studies examined possible associations between 118 folate
pathway-linked SNPs and NTDs. Boyles et al. (35) found a weak
association between betaine and homocysteine methyltransferase
(BHMT), which also remethylates homocysteine using betaine
rather than folate as the methyl donor, and NTD risk when
mothers were receiving pre-conceptional folate supplements or
when combined with the MTHFR (C677T ) TT homozygosity.
BHMT ’s role in NTD pathogenesis is poorly understood, but
may be related to altered cellular methylation potential and gene
expression. Shaw et al. (33) performed a candidate gene screen of
these 118 SNPs in a Californian population, and found a modest
association between spina bifida (NTD) risk and SNPs in seven
genes related to folate metabolism [BHMT, MTHFD1, MTHFD2,
MTHFR, MTRR, cystathionine-β-synthase (CBS), and thymidy-
late synthase (TYMS)]. For nearly all of these variants, (rare) allele
homozygosity can result in reduced folate metabolism and its end-
points. An additional analysis of these pathways using haplotype
and tagSNP screening approaches identified 68 SNPs associated
with NTD risk in genes from the folate metabolic pathway,MTHFR
and mitochondrial folate transporter (MFTC); DNA methyla-
tion, DNA (cytosine-5)-methyltransferase 3A (DNMT3A); B12
metabolism, Cubilin (CUBN ) and choline metabolism, phos-
phatidylethanolamine N -methyltransferase (PEMT ) (34).
In contrast, a number of studies have found no association
with some of these same gene variants. For example, a SNP in
the gene methionine synthase (MTR A2756G), in the enzyme
required for folate-dependent remethylation of homocysteine, was
initially shown to be significantly associated with increased risk
for spina bifida in a candidate gene study (58). However, Shaw
et al. (33) found no association MFTC is a component of the one-
carbon transport chain for which it was hypothesized that SNP
variants played a role in NTD risk by reducing folate metabo-
lism and DNA methylation. Pangilinan et al. (34) used a tagSNP
approach to assess MFTC ’s role in NTD development and found
a minor, but non-significant link with MFTC (R117H ). These
confounding observations and lack of a solid answer in these stud-
ies may be founded in gene–environment interactions and their
sometimes subtle effect on phenotype. For example, none of these
studies examined the modifying effect of nutrient intake or sta-
tus on the relationship between genotypes of interest and NTD
risk. The addition of dietary folate and folate status data may
resolve discrepancies between studies and improve the confidence
in results by providing accountability for a potentially significant
environmental factor.
www.frontiersin.org July 2014 | Volume 1 | Article 8 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zinck and MacFarlane Identification of genetic modifiers of nutrient status
CANCER
Low folate status has been associated with increased risk for
numerous cancers including colon and breast cancer. This asso-
ciation has raised questions including: “Does compromised DNA
repair lead to increased cancer risk?” “Could high dietary folate
increase the rate of tumor growth?”and“What role does folate con-
sumption or status play in individuals with low-frequency cancer
pre-disposition genotypes?”Much like the studies looking at NTDs
and folate-related genes, the relationship between cancer, nutrient
intake, and gene variants within enzymes involved in folate and
B-vitamin metabolism have relied heavily on both candidate gene
studies and GWAS (Tables 3 and 4).
Recent studies have examined the association between folate
status or consumption, which can be analyzed categorically or
continuously, and a limited suite of SNPs in folate-related genes
associated with lung, esophageal, stomach, colorectal, and kidney
cancers. Examples of key genes that have been studied include
MTHFR, MTHFD, MTR, MTRR, folate receptor 1 (FOLR1), and
fucosyltransferase 2 (FUT2; a gene associated with vitamin B12
status; Tables 2 and 3). The prototype gene studied in rela-
tionship to cancer is the MTHFR gene, and in particular the
C677T SNP. The gene product of MTHFR plays a key role in
folate metabolism, as it produces 5-methylTHF, which is used by
MTR for the production of THF and methionine. The MTHFR
C677T variant results in decreased levels of serum RBC folate
and elevated plasma homocysteine. Folic acid supplementation
can normalize folate status and enzyme activity, but absolute
folate status is lower than in those individuals with the wildtype
enzyme.
Since the implementation of folic acid fortification in the
United States and Canada (1996 and 1997, respectively), a slow-
down in the rate of colorectal cancer (CRC) decline has been
suggested to be due to high folic acid intake (65). This has
raised many questions regarding the role of folate in CRC risk.
Although many studies indicate that high folate status is associated
with reduced CRC risk, a handful has suggested that high lev-
els may increase CRC risk in persons with pre-cancerous legions.
Liu et al. (60) examined how interactions between folate-related
SNP variants and dietary intake (including folate) influence CRC
risk. Individuals with DNMT 1331V and low folate intake had
decreased CRC risk, while higher folate intake increased CRC risk,
due in part to enhanced abnormal methylation. The opposite was
observed for females with MTRR (122M ) homozygosity, a poten-
tial modifier of methionine metabolism. Han et al. (39) suggest
that significant pathway- and gene-level associations (ADA and
cysteine dioxygenase, CDO1) exist between one-carbon metabo-
lism genes and advanced colorectal adenoma in individuals with
extremely low folate intake. These findings could point to an asso-
ciation between CRC risk and altered homocysteine metabolism.
Alternatively, these markers may be in linkage-disequilibrium with
Table 3 | Major findings observed in association studies examining folate and vitamin B12 metabolic pathway genes, using candidate gene
studies, major diseases, and dietary folate or B12 dietary intake, including sample size, significance (as p or 95% confidence interval), and risk
measurement (Odds ratio, OR).
Topic Research Study Findings Sample Size Significance OR
NTD Doolin et al. (58) MTR (A2756G) NTD association Total: 209 95% CI: 0.92–5.06 2.16a
Boyles et al. (35) Weak association between BHMT variants (rs3733890,
rs558133) in folate rich environments and NTD risk.
Total: 304 p: 0.027, p: 0.036
Parle-McDermott et al. (55) DHFR association with decreased NTD risk. Cases: 283,
controls: 256
95% CI: 0.39–0.89 0.59
Parle-McDermott et al. (56) MTHFD1 (rs3832406) association with increased NTD risk. Triad n: 439 p: 0.002
Shaw et al. (33) Modest association between NTD risk and SNPs in BHMT,
CBS, MTHFD1, MTHFD2, MTHFR, MTRR, andTYMS.
Cases: 259,
controls: 359
p: 0.009–0.02
Pangilinan et al. (57) MTHFD1 R653Q (rs2236225) and MFTC (rs17803441)
significantly associated with increased NTD risk.
Cases: 301,
controls: 341
p: 0.0023, p: 0.0003
Pangilinan et al. (34) 68 SNPs associated with NTD risk including SNPs MFTC
( rs17803441), CDKN2A (rs3218009), ADA (rs2299686).
Cases: 301,
controls: 341
95% CI: 1.23–2.08,
p: 0.0098, p: 0.0004,
p: 0.0010
1.61
Cancer Flores et al. (59) CBS (rs2850146) and MTRR (rs3776467) SNPs may, in
combination with high folic acid levels, protect against lung
cancer.
Total: 907 95% CI: 1.98–12.2,
p: 0.0006
4.9
Liu et al. (60) DNMT 1331V and MTRR 122M significantly interacting with
dietary intake to modify CRC risk.
Cases: 1609,
controls: 1974
p: 0.04, p: 0.02
Pabalan et al. (61) No significant association between SHMT1 (rs1979277) or
folate levels and CRC risk.
Cases: 5043,
controls: 6311
p: 0.47–0.77
ar-Value used in place of OR.
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Table 4 | Major findings observed in association studies examining folate and vitamin B12 metabolic pathway genes, using GWAS, major
diseases and dietary folate and B12 dietary intake, including sample size, significance (as p or 95% confidence interval), and risk measurement
(Odds ratio, OR).
Topic Research Study Findings Sample Size Significance OR
NTD Grarup et al. (62) Whole genome and exome sequencing associated six novel loci with serum B12
(CD320, TCN2, ABCD4, MMAA, MMACHC ) or folate levels (FOLR3) with
cardiovascular diseases, cancers, and neurodegenerative disorders
Folate: 37341,
B12: 45576
p: 7.11×10−100 –
0.0018
Cancer Vollset et al. (36) No correlations between gastric cancer and plasma folate, total homocysteine
and serum B12. Slight increase in gastric cancer risk with MTHFR (rs1801133)
Cases: 245,
controls: 631
p: 0.04 1.47
Han et al. (39) SNPs in ADA (rs244072), CDO1 (rs34869) and FOLR1 (rs10501409) associated
with advanced colorectal adenoma in individuals with extremely low folate intake
Cases: 1331,
controls: 1501
p: 0.001,
p: 0.007, p: 0.008
Tanaka et al. (64) Significant associations between plasma B6 and ALPL (rs4654748), serum B12
and FUT (rs602662), and homocysteine and MTHFR (rs1801133)
n=2930 p: 8.30×10−18,
p: 2.83×10−20,
p: 4.36×10−13
Hazra et al. (63) Meta-analysis of 3 GWAS confirmed or identified strong associations between
B12 and FUT2 (rs602662, rs492602) and between plasma homocysteine and
MTHFR (rs1081133)
Total: 4763 p: 1.83×10−15,
p: 1.30×10−14,
p: 1.27×10−8
unsampled, but relevant genes. A meta-analysis of case–control
studies of the SHMT1 C1420T SNP found no significant associa-
tion between gene variants or folate levels and CRC risk (61). The
confounding outcomes suggest that further study of the gene–
gene interactions are required to resolve the factors leading to
pre-disposition and to identify the role of genotypic interactions
on phenotypic expression. Using a larger sample-set and/or high-
throughput methods may facilitate the study of these interactions
at very high resolutions.
Folate-gene association studies have identified more than 100
folate pathway SNPs related to digestive system cancers. In Euro-
pean populations, Vollset et al. (36) found a significant association
between the MTHFR (1298 A>C) SNP and increased risk of
gastric cancer, potentially due to significantly altered concentra-
tions of circulating folate and homocysteine. Using candidate gene
analysis, Zhang et al. (66) indicated that MTR (Ex26_20 A>G)
and MTRR (Ex5123 C>T) SNPs are associated with a borderline
increased risk of stomach cancer in the Polish population. These
polymorphisms may cause increased risk by altering homocysteine
to methionine conversions, subsequently increasing homocysteine
levels. No significant interactions were observed between dietary
folate intake and cancer risk. Though, the findings from both stud-
ies indicate that at least three SNP markers are associated with
digestive system cancers, their small sample size and regional loca-
tion may lead to population stratification artifacts, restricting how
the results can be extrapolated.
Ibiebele et al. (37) found that nutrient intake played a more
important role than gene variants in esophageal cancer risk.
Adequate folate intake reduced overall cancer risk, but supple-
mental folic acid and vitamin B12 was significantly associated
with increased Barrett’s esophagus and esophageal adenocarci-
nomas (37). No significant associations were observed between
SNPs from the MTHFR, MTRR, and MTR genes and cancer risk,
regardless of dietary intake, suggesting that diet may be the critical
factor in increasing the risks of these cancers.
Other studies have attempted to link folate metabolic pathway
genes with non-digestive tract cancers. Hu et al. (67) performed a
meta-analysis and determined that the MTRR A66G SNP was not
associated with breast cancer risk. A candidate gene study of the
MTHFR SNPs C677T and A1298C showed no significant associa-
tion with increased ovarian cancer risk in a case–control study of
American women (38). Flores et al. (59) determined, using a can-
didate gene SNP study, that SNPs in CBS (8283 G>C) and MTRR
(7068 A>G) have sex-specific associations with aberrant methy-
lation in the lung epithelium of smokers that could be mediated
by their effects on one-carbon metabolism and transsulfuration.
It was proposed that in rare cases these variations could act, in
combination with high folic acid levels, to protect against lung
cancer (68). All of these findings highlight the complex interaction
of dietary folate, vitamin B12, and homocysteine with genotypic
variation.
CARDIOVASCULAR DISEASE
The link between low intake and status of folate, B-vitamins, high
circulating homocysteine, and cardiovascular diseases, including
coronary heart disease and stroke has long been a topic of interest
(Table 4). The early findings of non-genomic studies suggested
that high homocysteine levels in the blood (hyperhomocysteine-
mia) were weakly correlated to increased risk of cardiovascular
disease (69). This has led to the hypothesis that folic acid and
B-vitamin supplementation could reduce the risk of cardiovascu-
lar disease by lowering homocysteine concentrations. Building on
these observations, various candidate gene and GWAS’s were con-
ducted to determine the genetic underpinnings of folate-related
cardiovascular disease. The focus of many of these studies was the
relationship between genotype and B-vitamin status, homocys-
teine levels, and cardiovascular disease. Early candidate gene stud-
ies found moderate risk associations between high homocysteine
and MTHFR C667T homozygosity, which would ultimately cause
an additional increase in homocysteine, and potentially contribute
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to increased risk for atherosclerosis and blood clot formation. (70).
Tanaka et al. (64) found associations between plasma B6 level and
ALPL (rs4654748 C>T: a component in B6 catabolism), plasma
B12 levels and FUT (rs602662 A>G: reduces B12 absorption), and
homocysteine levels and MTHFR C667T. This highlighted poten-
tial connections between these metabolic pathways. However, two
meta-analyses found no significant correlations between homo-
cysteine, the MTHFR C677T SNP, and cardiovascular risks (69,
71). The association between ALPL and MTHFR SNPs and homo-
cysteine, combined with homocysteine’s role in CVD risk, suggest
that these markers may be suitable predictors of plasma homo-
cysteine and also potentially CVD. Expanding the size of study
populations combined with new analytical approaches, including
continuous trait associations, may improve our ability to identify
SNPs that are suitable biomarkers for cardiovascular disease.
CAN SNPs ASSOCIATED WITH FOLATE AND B-VITAMIN
STATUS AND THEIR ASSOCIATED DISEASES PREDICT
FOLATE STATUS?
Our on-going work aims to tease apart the contributions of diet
and genetics on folate status and associated disease risk. Only
one past study (Table 3) has examined these interactions with
regards to folate using a single-marker. The MTHFR C677T SNP
was shown to reduce folate status and is associated with NTDs
and cancer, the risk of which can be mitigated by increased folate
intake. We are performing a moderately high-throughput analysis
to elucidate similar relationships between a panel of ~120 folate-
related SNPs and folate status and their modification by dietary
folate intake. The predictive power of key SNPs identified from
previous candidate gene and GWAS analyses will allow us to esti-
mate proportions of the population that may be most impacted
by folic acid intake from food fortification and supplement use.
This could include identifying groups that derive particular bene-
fit from the consumption of additional folic acid as well as those
individuals that may be at risk for over-exposure. Consideration
of folate intake may also reduce the ambiguity of results from pre-
vious studies that did not control for this obvious confounding
variable.
We have designed a two step analysis to address this issue using
DNA samples from the Canadian Health Measure Survey, cycle
1 with a samples size of approximately 3200 adults aged 20 years
and older. Information on the participants’ folate and vitamin B12
dietary intake and supplementation was collected, and red blood
cell folate, serum vitamin B12, and plasma total homocysteine were
measured. The first step of our analysis will examine the associ-
ation between candidate SNPs, which were previously associated
with nutrient status or disease, and the phenotypic variables red
blood cell folate, plasma vitamin B12, and plasma total homo-
cysteine using single-marker and multi-marker (haplotype and
gene–gene interaction) approaches. The multi-marker analysis
may reveal multi-gene interactions that influence an individual’s
nutrient status. The analysis will be expanded in the second step
with the addition of the environmental variables, including dietary,
and supplement intake of the nutrients, to identify SNPs that mod-
ify the expected relationship between nutrient intake and status.
Ultimately, we hope to refine our understanding of the relation-
ship between these SNPs and nutrient status by controlling for
nutrient intake, as well as identifying SNPs that may result in hypo-
or hyper-responsiveness to nutrient intake (e.g., SNPs that result
in lower or higher than expected status).
The data from studies such as we are performing will help to
inform, update, and refine policies, regulations, and recommenda-
tions to maximize the benefits of folic acid while minimizing the
risks of over-exposure to genetically susceptible sub-populations.
The general approach, we are proposing can be applied to other
nutrients and environmental factors to begin to understand the
implications of food policies and regulations for individuals in the
general population. The ultimate goal of public health policy is to
improve the quality of life and health for the majority of a given
population. Improved understanding of the relationship between
nutrient intake, genetic variation, and nutrient status or disease
may therefore allow for the refinement of nutrition policies.
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